VRTX Related Analyst EPS Change
-
Barclays Lowers Outlook on Idenix Pharmaceuticals (IDIX); Clarity on FDA Clinical Hold (BMY, VRTX, GILD)
-
UBS Cuts Estimates on Vertex (VRTX): Keep 'Buy' Thesis and Bullish View
-
Needham & Company Reiterates a 'Buy' on Vertex (VRTX); Incivek Sales Continue to Fall, But Initial ALS-2200 Data Are Encouraging
-
Needham & Company Maintains a 'Buy' on Vertex (VRTX); Adjusting Q2 Lower, But Positive on Cash Flow
-
Wells Fargo Upgrades Vertex (VRTX) to Outperform; Compelling CF Combo Data
-
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Q1 Preview
-
UBS Maintains a 'Neutral' on Vertex (VRTX); Potential CF Program Advancement
Back to VRTX Stock Lookup
